These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12448654)

  • 41. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors.
    Berlin JD; Alberti DB; Arzoomanian RZ; Feierabend CA; Simon KJ; Binger KA; Marnocha RM; Wilding G
    Invest New Drugs; 1998-1999; 16(4):325-30. PubMed ID: 10426665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
    Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
    Awada A; Biganzoli L; Cufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    Eur J Cancer; 2002 Apr; 38(6):773-8. PubMed ID: 11937310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
    Alberts SR; Erlichman C; Sloan J; Okuno SH; Burch PA; Rubin J; Pitot HC; Goldberg RM; Adjei AA; Atherton PJ; Kaufmann SH
    Ann Oncol; 2001 May; 12(5):627-31. PubMed ID: 11432620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
    Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
    Czito BG; Hong TJ; Cohen DP; Petros WP; Tyler DS; Pappas TN; Yu D; Lee CG; Lockhart AC; Morse MA; Fernando N; Hurwitz HI
    Cancer Invest; 2006 Feb; 24(1):9-17. PubMed ID: 16466986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
    Karampeazis A; Vamvakas L; Agelaki S; Kentepozidis N; Papadimitraki E; Gioulbasanis I; Vardakis N; Ignatiadis M; Mavroudis D; Georgoulias V
    Oncology; 2006; 71(5-6):347-53. PubMed ID: 17785992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
    Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
    Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
    Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
    Oettle H; Pelzer U; Hochmuth K; Diebold T; Langrehr J; Schmidt CA; Arning M; Vogl TJ; Neuhaus P; Huhn D; Riess H
    Anticancer Drugs; 1999 Sep; 10(8):699-704. PubMed ID: 10573201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
    Ullenhag GJ; Rossmann E; Liljefors M
    PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
    Madajewicz S; Hentschel P; Burns P; Caruso R; Fiore J; Fried M; Malhotra H; Ostrow S; Sugarman S; Viola M
    J Clin Oncol; 2000 Oct; 18(20):3553-7. PubMed ID: 11032598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
    Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
    J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.